共查询到10条相似文献,搜索用时 125 毫秒
1.
Ota M Tsujikawa A Miyamoto K Sakamoto A Murakami T Yoshimura N 《Japanese journal of ophthalmology》2010,54(6):555-564
Purpose
To study prognostic factors for visual acuity (VA) after intravitreal bevacizumab injection (IVB) for macular edema (ME) associated with retinal vein occlusion (RVO), by evaluating the correlation between the final VA and VA at baseline and at 1, 3, and 6 months after the initial IVB. 相似文献2.
S. Aisenbrey F. Ziemssen M. Völker F. Gelisken P. Szurman G. Jaissle S. Grisanti K. U. Bartz-Schmidt 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2006,245(7):941-948
Background The purpose of the study is to report data on short-term safety of intravitreal bevacizumab treatment and its effect on visual
function, central retinal thickness, and angiographical changes of occult choroidal neovascularization due to age-related
macular degeneration.
Methods A consecutive interventional case series of 30 patients with active subfoveal occult choroidal neovascularization secondary
to age-related macular degeneration was followed after one intravitreal injection of 1.25 mg bevacizumab at baseline and subsequent
injections following standardized criteria. At baseline and follow-up visits patients had visual acuity assessment, intraocular
pressure measurement, fluorescein angiography, and optical coherence tomography imaging.
Results No serious ocular or systemic adverse events were identified. A significant increase of intraocular pressure or signs of retinal
toxicity or endophthalmitis were not detected in any patient. Optical coherence tomography revealed significant decrease (p < 0.001)
in central retinal thickness after 1 week, 4 weeks, and 12 weeks, respectively. Fluorescein leakage decreased within 1 week
and improvement was maintained at week 12 in the majority of patients. Visual acuity improved or remained stable in 29 of
30 patients; improvement of 3 or more lines was seen in 14 of 30 patients; one patients showed improvement of 6 lines. No
patient had severe vision loss of 6 lines or more; moderate vision loss of 3 lines was seen in one patient. Re-injections
of bevacizumab according to standard criteria were performed one to two times during the follow-up period of 12 weeks with
a re-injection interval of 4 to 18 weeks (median 8 weeks).
Conclusions Short-term results suggest that intravitreal injection of bevacizumab is well tolerated and for the majority of patients with
occult choroidal neovascularization in AMD results in improvement of visual acuity, decrease in central retina thickness,
and reduction of angiographic leakage of the lesion. Bevacizumab as intravitreal treatment may provide a novel therapeutic
option for selected patients with exudative AMD. Randomized prospective multicenter trials seem justified to further evaluate
long term effects and impact of intravitreal bevacizumab on different subtypes of AMD compared to established therapies. 相似文献
3.
目的:评价玻璃体腔注射曲安奈德治疗视网膜静脉阻塞合并黄斑水肿的疗效及并发症。方法:患者30例30眼玻璃体腔注射曲安奈德4mg治疗视网膜静脉阻塞合并黄斑水肿,观察治疗前、后的最佳矫正视力、眼压、裂隙灯显微镜检查、眼底荧光血管造影和光学相干断层扫描的变化,采用SPSS 12.0软件进行统计学分析。结果:所有患者手术后视力均显著提高,平均黄斑中心凹厚度(CMT)显著减少。病程、年龄、注射前CMT及视网膜静脉阻塞的类型和视力预后无相关性,注射前视力与注射后末次视力呈正相关。结论:玻璃体腔注射曲安奈德治疗视网膜静脉阻塞合并黄斑水肿简单、安全、易操作,短期内可以迅速减轻黄斑水肿,最终的视力预后取决于治疗前的视力,部分患者在注射后3 ~6mo可能复发。 相似文献
4.
Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study 总被引:1,自引:0,他引:1
PURPOSE:: Bevacizumab is a monoclonal antibody to vascular endothelial growth factor (VEGF) which has been successfully used for the treatment of age-related macular degeneration with choroidal neovascularization. As VEGF is involved in the pathomechanisms of inflammation and endothelial dysfunction the authors used bevacizumab as a last resort treatment in patients with persistent uveitic cystoid macular edema (CME). PATIENTS AND METHODS:: Persistent uveitic CME was defined by optical coherence tomography (OCT) measurements >250 mum despite previous treatments. The authors reviewed patients with persistent CME who subsequently had been treated with intravitreous bevacizumab 1.25 or 2.5 mg. Improvement was judged by visual acuity (VA) gain >/=2 lines and thickness reduction in OCT. RESULTS:: Eleven eyes of 10 patients were injected since February 2006. Median follow-up was 70 days. Reduction in central retinal thickness could be seen as early as 2 weeks with a mean foveal thickness reduction of 127.2 mum at 4 weeks. Concurrent improvement in VA was seen in 4 of 10 patients, and was unchanged in the others. Four patients received two injections and five patients received three injections. Except for progression of cataract in one eye no ocular or systemic adverse events were recorded. CONCLUSIONS:: Intravitreal bevacizumab seems to be an effective and safe treatment in the management of refractory inflammatory CME. The effect is transient, and reinjections may be necessary, although the time until reinjection is needed differs individually. 相似文献
5.
Seul Gi Yoo Jae Hui Kim Tae Gon Lee Chul Gu Kim Jong Woo Kim 《Indian journal of ophthalmology》2015,63(1):25-29
Aims:
To evaluate the 1-month efficacy of intravitreal triamcinolone acetonide (TA) in treating macular edema secondary to retinal vein occlusion (RVO) that was refractory to intravitreal bevacizumab.Materials and Methods:
This retrospective, observational study included 23 eyes from 23 patients with macular edema secondary to RVO. Macular edema that did not respond to two or more consecutive intravitreal bevacizumab injections was treated with intravitreal TA. Central foveal thickness (CFT) and best-corrected visual acuity (BCVA) were compared before and one month after TA injection.Results:
Fifteen eyes were diagnosed with central RVO, and eight eyes were diagnosed with branch RVO. All patients were previously treated with 2.4 ± 0.6 intravitreal bevacizumab injections. The TA injection was performed, on average, 5.8 ± 1.4 weeks after the last bevacizumab injection. The CFT before TA injection was 516.6 ± 112.4 μm and significantly decreased to 402.3 ± 159.7 μm after TA therapy (P < 0.001). The logarithm of the minimal angle of resolution BCVA was 0.72 ± 0.34 before TA therapy and was not significantly improved by the treatment (0.67 ± 0.35, P = 0.119), despite a decrease in CFT. However, seven eyes (30.4%) had a BCVA gain of one or more lines.Conclusions:
Intravitreal TA therapy was beneficial in some patients with macular edema secondary to RVO that was refractory to intravitreal bevacizumab therapy. This study suggests that intravitreal TA should be considered as a treatment option for refractory macular edema. 相似文献6.
Suk H Byeon Young A Kwon Hyun-Sub Oh Min Kim Oh W Kwon 《Journal of ocular pharmacology and therapeutics》2007,23(4):387-394
OBJECTIVE: The aim of this study was to identify the short-term effect, safety, and durability of intravitreally injected bevacizumab in patients with macular edema (ME) caused by retinal vein obstruction (RVO) and diabetic macular edema (DME). METHODS: We retrospectively evaluated 39 eyes of 36 patients, 14 with ME caused by RVO and 25 with DME, who received intravitreal bevacizumab (1.25 mg) and were followed up for at least 3 months. Monthly assessments examined safety, best corrected visual acuity with an ETDRS chart (logMAR), and central retinal thickness (CRT) using optical coherence tomography. RESULTS: No significant ocular or systemic side-effects were observed. The follow-up period was 5.4 +/- 1.1 months (mean +/- standard deviation). During follow-up, the mean number of injections was 1.4 +/- 0.5. The baseline mean logMAR was 0.91 +/- 0.51, and the mean CRT was 552.6 +/- 186.7 microm. At 1, 2, and 3 months, the mean logMAR was 0.67 +/- 0.46 (paired t test, P < 0.001), 0.66 +/- 0.46 (P < 0.001), and 0.69 +/- 0.45 (P < 0.001), respectively, and the mean CRT was 323.1 +/- 151.9 mum (P < 0.001), 324.6 +/- 136.9 mum (P < 0.001), and 382.5 +/- 130.4 microm (P < 0.001), respectively. Fourteen (14) of 34 eyes with more than 3 months of follow-up required a second injection at a mean 3.4 +/- 1.0 months after the initial injection. For both ME caused RVO and DME patients, a bevacizumab administration improved logMAR and CRT at each time point through to 6 months, except for logMAR in DME at 1 week (P = 0.081), 5 months (P = 0.130) and 6 months (P = 0.759). CONCLUSIONS: An intravitreal bevacizumab injection for ME caused by RVO and DME was safe and effective for improving visual acuity and reducing CRT. 相似文献
7.
8.
目的观察玻璃体腔内注射Bevacizumab联合眼底激光治疗视网膜静脉阻塞(RVO)继发黄斑水肿的安全性及临床疗效。方法回顾性系列病例研究。确诊的RVO继发黄斑水肿患者共30例(30眼),其中分支静脉阻塞20例,中央静脉阻塞10例。年龄34—79岁,平均(57.3+8.9)岁。玻璃体腔内注射Bevacizumab的剂量按照PrONTO研究组方法,为1.25mg,3次注射后,根据眼底荧光造影(FFA)结果补充眼底激光治疗。治疗前和治疗后1、3、6、12个月对患者进行视力、眼底照相、相干光学断层扫描、FFA检查。采用ETDRS视力表进行视力检查;采用光学相关断层扫描仪测量黄斑区视网膜神经上皮层厚度(CRT)。患者治疗后各个时间点的最佳矫正视力(BCVA)、CRT值与治疗前基线值比较采用配对t检验,RVO患者各个时间点的BCVA与CRT值的相关性采用直线回归分析。结果30例RVO患者平均接受玻璃体腔内注射(3.9±1.9)次,视力提高15个字符及以上者16眼(54%),视力提高5。lO个字符者10眼(33%),视力稳定在5个字符以内者4眼(13%)。治疗后12个月时,ETDRS视力为60±19,与治疗前(42±19)相比,差异有统计学意义(f=7.87,P〈O.05)。平均CRT值末次随访时为(268.9±115.9)μm,与治疗前[(616.7±177.0)μm]相比,差异有统计学意义(t=13.23,P〈O.01)。治疗后12个月BCVA与治疗前BCVA的相关性存在统计学意义(r=0.791,P〈0.01),无论何种类型静脉阻塞,基线视力、预后视力与治疗前黄斑水肿程度均无相关性。末次随访时21眼(70%)黄斑区未见明显囊性积液,9眼(30%)仍有少量囊性积液,FFA显示复发的主要原因为黄斑区小血管渗漏。治疗及随访过程中未见明显不良反应发生。结论对RVO继发黄斑水肿患者进行玻璃体腔内注射Bevacizumab联合眼底激光治疗,可保存或改善视力,有效减轻黄斑水肿;黄斑区毛细血管渗漏是引起黄斑水肿复发的主要原因,所以重复玻璃体腔注射是必需的。 相似文献
9.
Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study 总被引:5,自引:0,他引:5
Costa RA Jorge R Calucci D Melo LA Cardillo JA Scott IU 《Retina (Philadelphia, Pa.)》2007,27(2):141-149
PURPOSE: To evaluate the safety, visual acuity changes, and morphologic effects associated with intravitreal bevacizumab injections for the management of macular edema due to ischemic central or hemicentral retinal vein occlusion (RVO). METHODS: In this prospective, open-label study, 7 consecutive patients (7 eyes) with macular edema associated with ischemic central or hemicentral RVO were treated with intravitreal injections of 2.0 mg (0.08 mL) of bevacizumab at 12-week intervals. Standardized ophthalmic evaluation was performed at baseline and at weeks 1, 6, and 12 after each injection. Clinical evidence of toxicity and complications as well as changes in logarithm of minimum angle of resolution Early Treatment Diabetic Retinopathy Study best-corrected visual acuity (BCVA), central macular thickness (CMT) and total macular volume (TMV) shown by optical coherence tomography (OCT), and dye leakage shown by fluorescein angiography were evaluated. RESULTS: The median age of the 7 patients was 65 years (range, 58-74 years), and the median duration of symptoms before injection was 7 months (range, 2.5-16 months). At baseline, mean BCVA was 1.21 (Snellen equivalent, approximately 20/320) in the affected eye. Mean baseline CMT and TMV were 730.1 microm and 17.1 mm(3), respectively. Fluorescein leakage was observed in the macula and affected retinal quadrants in all seven eyes. Six patients completed the 25-week follow-up examination with reinjections performed at weeks 12 and 24. The most common adverse events were conjunctival hyperemia and subconjunctival hemorrhage at the injection site. At the last follow-up, mean BCVA in the affected eye was 0.68 (Snellen equivalent, 20/100(+1). No patient had a decrease in BCVA. Mean CMT and TMV at the 25-week follow-up were 260.3 microm and 9.0 mm(3), respectively; fluorescein leakage within the macula and affected retinal quadrants as compared with baseline was markedly reduced in all patients. Coupled with fluorescein angiographic findings, OCT data suggest a trend of macular edema recurrence between 6 weeks and 12 weeks after injection. CONCLUSIONS: Intravitreal bevacizumab injections of 2.0 mg at 12-week intervals were well tolerated and were associated with short-term BCVA stabilization or improvement and favorable macular changes in all patients with ischemic RVO and associated macular edema. 相似文献
10.
Schaal KB Höh AE Scheuerle A Schütt F Dithmar S 《Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft》2007,104(4):285-289
BACKGROUND: Retinal vein occlusion often leads to macular edema as a result of an elevated level of intravitreal VEGF. We report on the anatomic and functional results after intravitreal bevacizumab injections in patients with retinal vein occlusion. METHODS: In a prospective study, 18 patients with central, and 22 patients with branch retinal vein occlusion, all of whom had persistent macular edema (>300 microm) received 2.5 mg intravitreal bevacizumab. ETDRS visual acuity, ophthalmic examination and stratus OCT were performed at baseline, 1 week after injection and then monthly. Further injections were given every 6 weeks in patients with persistent or recurring macular edema.RESULTS: The findings did not deteriorate in any of the 40 patients. The injections (mean of 2.6+/-1.4 injections/patient) were very well tolerated in all cases during a mean follow-up of 23+/-13 weeks. On the last visit, 73.3% of patients with central retinal vein occlusion and 76.5% of those with branch retinal vein occlusion were found to have significantly improved visual acuity (by at least 3 lines). Mean central retinal thickness had decreased from 921+/-264 to 239+/-66.2 microm in patients with central retinal vein occlusion, and from 678+/-221 to 236+/-78 microm in patients with branch retinal vein occlusion.CONCLUSIONS: Neither intraocular nor systemic side-effects were observed in this study after repeated intravitreal injections of 2.5 mg bevacizumab. Current results suggest that intravitreal anti-VEGF therapy is a promising option in macular edema secondary to retinal vein occlusion. 相似文献